GLP-1 receptor agonists reduce cardiovascular events in people without obesity or established cardiovascular disease.
- Current status
- Insufficient evidenceEvidence stable · Cardiovascular
- Why
- No outcome trial has enrolled such a population. REWIND enrolled only people with type 2 diabetes; the umbrella review covered only people with overweight or obesity.
- What would change it
- A randomized primary-prevention outcome trial in adults without obesity or diabetes.
- Linked studies
- 2 · 2 doesn't directly test the claim
- Last updated
- Oct 19, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
The evidence, sorted by what it shows
Doesn't directly test the claim (2)
- Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
Umbrella review of RCT meta-analyses in people with overweight or obesity: GLP-1 RAs reduced MACE and MI with high-certainty evidence, but these associations were no longer significant among participants without CVD at baseline. It included no people without obesity, so it does not test the claim.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialRandomized trial · 2019 · Study tier 1 · Different population · Benefit · Industry funded
REWIND, adults aged 50 or older with type 2 diabetes with or without prior cardiovascular disease: dulaglutide reduced the composite of non-fatal MI, non-fatal stroke or cardiovascular death (HR 0.88, 95% CI 0.79-0.99), while all-cause mortality did not differ (HR 0.90, 95% CI 0.80-1.01). All participants had diabetes and the trial did not select for normal weight, so it does not test the claim.
How this assessment has changed
- Insufficient evidenceOct 19, 2026 · Evidence stable
Owner decision 2026-10-18 on IN-061 (claims audit): recommended options accepted (IN-061.24). Status unchanged; rationale corrected to match the audited links.
- Insufficient evidenceSep 13, 2026 · Evidence stable
initial curated status